Search

Your search keyword '"Kudoh, Tooru"' showing total 130 results
Start Over Author "Kudoh, Tooru"
130 results on '"Kudoh, Tooru"'

1. Acute and late toxicities of pirarubicin in the treatment of childhood acute lymphoblastic leukemia: results from a clinical trial by the Japan Association of Childhood Leukemia Study

Author

Hori, Hiroki, Kudoh, Tooru, Nishimura, Shinichiro, Oda, Megumi, Yoshida, Makoto, Hara, Junichi, Tawa, Akio, Usami, Ikuya, Tanizawa, Akihiko, Yumura-Yagi, Keiko, Kato, Koji, Kobayashi, Ryoji, Komada, Yoshihiro, Matsuo, Keitaro, Horibe, Keizo, and For the Japan Association of Childhood Leukemia Study

Published
2017
Full Text
View/download PDF

3. Risk-adjusted therapy for pediatric non-T cell ALL improves outcomes for standard risk patients: results of JACLS ALL-02

Author

Hasegawa, Daiichiro, Imamura, Toshihiko, Yumura-Yagi, Keiko, Takahashi, Yoshihiro, Usami, Ikuya, Suenobu, So-Ichi, Nishimura, Shinichiro, Suzuki, Nobuhiro, Hashii, Yoshiko, Deguchi, Takao, Moriya-Saito, Akiko, Kato, Koji, Kosaka, Yoshiyuki, Hirayama, Masahiro, Iguchi, Akihiro, Kawasaki, Hirohide, Hori, Hiroki, Sato, Atsushi, Kudoh, Tooru, Nakahata, Tatsutoshi, Oda, Megumi, Hara, Junichi, Horibe, Keizo, Hasegawa, Daiichiro, Imamura, Toshihiko, Yumura-Yagi, Keiko, Takahashi, Yoshihiro, Usami, Ikuya, Suenobu, So-Ichi, Nishimura, Shinichiro, Suzuki, Nobuhiro, Hashii, Yoshiko, Deguchi, Takao, Moriya-Saito, Akiko, Kato, Koji, Kosaka, Yoshiyuki, Hirayama, Masahiro, Iguchi, Akihiro, Kawasaki, Hirohide, Hori, Hiroki, Sato, Atsushi, Kudoh, Tooru, Nakahata, Tatsutoshi, Oda, Megumi, Hara, Junichi, and Horibe, Keizo

Abstract

This study was a second multicenter trial on childhood ALL by the Japan Childhood Leukemia Study Group (JACLS) to improve outcomes in non-T ALL. Between April 2002 and March 2008, 1138 children with non-T ALL were enrolled in the JACLS ALL-02 trial. Patients were stratified into three groups using age, white blood cell count, unfavorable genetic abnormalities, and treatment response: standard risk (SR), high risk (HR), and extremely high risk (ER). Prophylactic cranial radiation therapy (PCRT) was abolished except for CNS leukemia. Four-year event-free survival (4yr-EFS) and 4-year overall survival (4yr-OS) rates for all patients were 85.4% ± 1.1% and 91.2% ± 0.9%, respectively. Risk-adjusted therapy resulted in 4yr-EFS rates of 90.4% ± 1.4% for SR, 84.9% ± 1.6% for HR, and 66.5% ± 4.0% for ER. Based on NCI risk classification, 4yr-EFS rates were 88.2% in NCI-SR and 76.4% in NCI-HR patients, respectively. Compared to previous trial ALL-97, 4yr-EFS of NCI-SR patients was significantly improved (88.2% vs 81.2%, log rank p = 0.0004). The 4-year cumulative incidence of isolated (0.9%) and total (1.5%) CNS relapse were significantly lower than those reported previously. In conclusion, improved EFS in NCI-SR patients and abolish of PCRT was achieved in ALL-02.

Published
2020

4. Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia Study (JACLS) ALL F-protocol

Author

Suzuki, Nobuhiro, Yumura-Yagi, Keiko, Yoshida, Makoto, Hara, Junichi, Nishimura, Shinichiro, Kudoh, Tooru, Tawa, Akio, Usami, Ikuya, Tanizawa, Akihiko, Hori, Hiroki, Ito, Yasuhiko, Miyaji, Ryosuke, Oda, Megumi, Kato, Koji, Hamamoto, Kazuko, Osugi, Yuko, Hashii, Yoshiko, Nakahata, Tatsutoshi, and Horibe, Keizo

Published
2010
Full Text
View/download PDF

14. Continuous Cytarabine Plus Dexamethasone in Consolidation Phase to Patients with Childhood ALL: Result from Japan Association of Childhood Leukemia Study - JACLS ALL02 Protocol -

Author

Suenobu, So-ichi, primary, Usami, Ikuya, additional, Imamura, Toshihiko, additional, Kawasaki, Hirohide, additional, Yagi, Keiko Yumura, additional, Nishimura, Shinichiro, additional, Kaneda, Makoto, additional, Takahashi, Yoshihiro, additional, Hasegawa, Daiichiro, additional, Suzuki, Nobuhiro, additional, Hashii, Yoshiko, additional, Deguchi, Takao, additional, Akiko, Saito, additional, Kato, Koji, additional, Kosaka, Yoshiyuki, additional, Endo, Mikiya, additional, Iguchi, Akihiro, additional, Oda, Megumi, additional, Hori, Hiroki, additional, Sato, Atsushi, additional, Nakahata, Tatsutoshi, additional, Kudoh, Tooru, additional, Hara, Junichi, additional, and Horibe, Keizo, additional

Published
2016
Full Text
View/download PDF

15. Human parvovirus B19 and meningoencephalitis

Author

Tsutsumi, Hiroyuki, Haseyama, Keiji, Kudoh, Tooru, and Yoto, Yuko

Subjects
Meningoencephalitis -- Risk factors, Parvovirus infections -- Physiological aspects
Published
2001

19. Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia Study (JACLS) ALL F‐protocol

Author

Suzuki, Nobuhiro, primary, Yumura‐Yagi, Keiko, additional, Yoshida, Makoto, additional, Hara, Junichi, additional, Nishimura, Shinichiro, additional, Kudoh, Tooru, additional, Tawa, Akio, additional, Usami, Ikuya, additional, Tanizawa, Akihiko, additional, Hori, Hiroki, additional, Ito, Yasuhiko, additional, Miyaji, Ryosuke, additional, Oda, Megumi, additional, Kato, Koji, additional, Hamamoto, Kazuko, additional, Osugi, Yuko, additional, Hashii, Yoshiko, additional, Nakahata, Tatsutoshi, additional, and Horibe, Keizo, additional

Published
2009
Full Text
View/download PDF

21. Effective Risk-Adapted Therapy for Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL) with the Japan Association of Childhood Leukemia Study (JACLS) ALL-97 Protocol.

Author

Horibe, Keizo, primary, Kudoh, Tooru, additional, Hori, Hiroki, additional, Nishimura, Shinichiro, additional, Oda, Megumi, additional, Yoshida, Makoto, additional, Komada, Yoshihiro, additional, Hara, Junichi, additional, Tawa, Akio, additional, Usami, Ikuya, additional, Tanizawa, Akihiko, additional, and Yumura-Yagi, Keiko, additional

Published
2006
Full Text
View/download PDF

22. Improved Outcome of Childhood Acute Lymphoblastic Leukemia (ALL) with Induction Failure Treated on the Japan Association of Childhood Leukemia Study (JACLS) ALL F-Protocol.

Author

Suzuki, Nobuhiro, primary, Yumura-Yagi, Keiko, additional, Hara, Junichi, additional, Yoshida, Makoto, additional, Nishimura, Shinichiro, additional, Kudoh, Tooru, additional, Tawa, Akio, additional, Usami, Ikuya, additional, Tanizawa, Akihiko, additional, Hori, Hiroki, additional, Ito, Yasuhiro, additional, Miyaji, Ryosuke, additional, Komada, Yoshihiro, additional, Oda, Megumi, additional, and Horibe, Keizo, additional

Published
2006
Full Text
View/download PDF

23. Treatment of Stage IV Malignant Rhabdoid Tumor of the Kidney (MRTK) With ICE and VDCy

Author

Yamamoto, Masaki, primary, Suzuki, Nobuhiro, additional, Hatakeyama, Naoki, additional, Mizue, Nobuo, additional, Hori, Tsukasa, additional, Kuroiwa, Yuki, additional, Hareyama, Masato, additional, Oda, Takanori, additional, Kudoh, Tooru, additional, Nui, Akihiro, additional, Matsuno, Takashi, additional, Hirama, Toshinori, additional, Yokoyama, Shigeaki, additional, Dome, Jeffrey S., additional, and Tsutsumi, Hiroyuki, additional

Published
2006
Full Text
View/download PDF

30. Human parvovirus B19 infection and hepatitis

Author

Naides, StanleyJ., primary, Karetnyi, YuoryV., additional, Cooling, LauraL.W., additional, Mark, RodneyS., additional, Langnas, AlanN., additional, Yoto, Yuko, additional, Kudoh, Tooru, additional, Haseyama, Keiji, additional, Suzuki, Nobuhiro, additional, and Chiba, Shunzo, additional

Published
1996
Full Text
View/download PDF

40. Neuraminidase activity in liver and brain from patients with i-cell disease

Author

Kudoh Tooru, Oyanagi Kazuhiko, Minami Ryoji, and Nakao Tooru

Subjects
Clinical Biochemistry, Neuraminidase, Biology, Biochemistry, Substrate Specificity, chemistry.chemical_compound, Mucolipidoses, Isotonic, medicine, Humans, Lactose, Mucolipidosis, Biochemistry (medical), Brain, General Medicine, beta-Galactosidase, medicine.disease, Molecular biology, Kinetics, Liver, chemistry, biology.protein, Neuraminidase activity, I-cell disease
Abstract

The activity of neuraminidase in liver and brain from I-cell disease (Mucolipidosis II) was investigated. Neuraminidase activities using two substrates [alpha-L-N-acetylneuraminosyl(2 leads to 3)lactose and alpha-L-N-acetylneuraminosyl(2 leads to 6)lactose] were reduced in the supernatant and sedimentable fractions obtained in isotonic KCl. The activity of beta-D-galactosidase was also reduced in the liver; on the other hand, both neuraminidase fractions were normal, although beta-galactosidase activities were markedly reduced. In view of these results, it is suggested that the defect of neuraminidase is not directly responsible for the primary etiology of I-cell disease.

Published
1979

41. Biochemical Studies in a Patient with Subacute Neuropathic Gaucher Disease without Visceral Glucosylceramide Storage

Author

Wenger, David A, Roth, Sandra, Kudoh, Tooru, Grover, Warren D, Tucker, Samuel H, Kaye, Edward M, and David Ullman, M

Abstract

Summary: Autopsy samples were obtained from a 12.5-year-old girl who died with a neurologic disorder consisting of myoclonus, myoclonic epilepsy, spasticity, strabismus, and mild mental retardation but no hepatosplenomegaly. Studies in leukocytes, cultured skin fibroblasts, brain, liver, and spleen of this patient revealed glucosylceramide ß-glucosidase (EC 3.2.1.45, glucocerebrosidase) activity about 10% of controls, and well in the range found in samples from Gaucher disease patients. Extraction of the lipids from liver and spleen with chloroform-methanol (2:1) did not show accumulation of glucosylceramide or other lipid. Examination of the lipids in brain by high performance liquid chomatography revealed the presence of glucosylceramide, which is not found in brain samples from controls. Pathologic examination of the liver and spleen revealed no evidence of Gaucher disease. The brain showed many degenerative lesions and loss of neurons. There was no complementation of glucocerebrosidase activity when the cells from this patient were hybridized with cells from patients with Type 1 or Type 2 Gaucher disease. The reason for the lack of glucosylceramide storage in the liver and spleen has not been determined.

Published
1983
Full Text
View/download PDF

42. Identification of keratan sulfate in liver affected by Morquio syndrome

Author

Nakao Tooru, Minami Ryoji, Tsugawa Satosi, Oyanagi Kazuhiko, Kudoh Tooru, and Abo Katsuyuki

Subjects
Male, medicine.medical_specialty, Morquio syndrome, Adolescent, Keratan sulfate, Clinical Biochemistry, Biochemistry, Glycosaminoglycan, chemistry.chemical_compound, Internal medicine, medicine, Chondroitin, Humans, Child, Glycosaminoglycans, Biochemistry (medical), Chondroitin Sulfates, Mucopolysaccharidosis IV, General Medicine, Heparan sulfate, Electrophoresis, Cellulose Acetate, Syndrome, medicine.disease, carbohydrates (lipids), Molecular Weight, Endocrinology, chemistry, Liver, Keratan Sulfate, Chromatography, Gel, Female
Abstract

Glycosaminoglycan content, composition and molecular weight were determined in liver obtained from a patient with Morquio syndrome (Mucopolysaccharidosis IV). There was about a four-fold increase in glycosaminoglycan content (as hexosamine) of the affected liver as compared to the control liver. The major glycosaminoglycan accumulated in the liver was keratan sulfate, which was not found in the control liver. Chondroitin sulfates, especially chondroitin 6-sulfate, were also increased. Heparan sulfate isolated from the liver of a patient with Morquio syndrome was structurally different to that from control liver, and the glycosaminoglycans from Morquio syndrome were of a much lower molecular weight than those from control.

Published
1979

Catalog

Books, media, physical & digital resources
See catalog results